Two faces of p53: aging and tumor suppression.
Level 5 - mechanism / opinion, no new human data
Narrative review discussing mechanistic pathways without primary clinical or empirical data.
PubMed 17942417 · doi:10.1093/nar/gkm744
What was done
This narrative review synthesizes literature on mammalian p53 signaling in response to DNA damage, examining how downstream activation of apoptosis and cellular senescence balances tumor suppression against tissue aging.
What was found
No quantitative data or sample sizes are reported in the abstract. The authors describe how p53-driven apoptosis and senescence prevent neoplastic transformation, but simultaneously deplete stem and progenitor cell pools and allow persistent senescent cells to alter tissue microenvironments, potentially accelerating organismal aging.
Why it matters
The review outlines the trade-off between cancer protection and aging driven by p53 activity. Understanding this balance is critical when considering therapeutic interventions targeting p53 pathways or cellular senescence.
Limits
This is a narrative review presenting mechanistic and conceptual models with no primary human or experimental data provided in the abstract. Quantitative effects, sample sizes, and specific experimental systems are not described.
Cited by
- supports Mutations in genes that regulate senescence-associated cell growth arrest lead to early cancer-related death in both mice and humans.